FFA/NEFA Cancer Research Results

FFA/NEFA, Free fatty acids — FFA / non-esterified fatty acids, NEFA: Click to Expand ⟱
Source:
Type: Biomarker
Free fatty acids may be measured in plasma, tumour tissue, culture medium, or intracellular lipid pools. They provide substrates for:

β-oxidation and ATP production;
membrane lipid synthesis;
lipid signalling;
eicosanoid production;
protein acylation.

However, excessive FFAs can cause lipotoxicity, ROS generation, ER stress, lipid peroxidation, or ferroptosis. Therefore, FFA ↑ is not automatically tumour-promoting or beneficial.


Scientific Papers found: Click to Expand⟱
6984- Form,    Formononetin suppresses colitis-associated colon cancer by targeting lipid synthesis and mTORC2/Akt signaling
- in-vitro, Colon, HCT116 - Review, IBD, RAW264.7
*Inflam↓, AntiCan↑, *NF-kB↓, *MAPK↓, *colonLen↑, TumCG↓, Apoptosis↑, LC3II↑, Beclin-1/ATG6↑, cl‑Casp3↑, BAX↑, Bcl-2↓, IGF-1↓, ACLY↓, Acetyl-CoA↓, Fas↓, HSL/LIPE↓, ATGL/PNPLA2↓, FFA/NEFA↓, GSK‐3β↑, p‑mTOR↓, Rictor↓, p‑Akt↓, PDE3B↓, p‑PKA↓, p‑HSL/LIPE↑, TumAuto↑,
7630- Ins,    Modulation of both Insulin Resistance and Cancer Growth by Inositol
- Review, Var, NA - Review, Diabetic, NA
*IRes↓, *AntiDiabetic↑, *glucose↝, AntiCan↑, PI3K↓, Akt↓, Glycolysis↓, STK11/LKB1↑, *FASN↓, *LDL↓, *FFA/NEFA↓, *ROS↓, ROS↑, IGF-1↓,
8110- L-Orn,    L-ornithine supplementation attenuates physical fatigue in healthy volunteers by modulating lipid and amino acid metabolism
- Trial, Nor, NA
*Dose↝, *KeyT↝, *FFA/NEFA↝, *NH3↓, *fatigue↓,
9086- MGF,    Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial
- Trial, Obesity, NA
*Dose↝, *TG/TAG↓, *FFA/NEFA↓, *IRes↓,
9058- PatchO,    Patchouli oil isolated from the leaves of Pogostemon cablin ameliorates ethanol-induced acute liver injury in rats via inhibition of oxidative stress and lipid accumulation
- in-vivo, LiverDam, NA
*hepatoP↑, *ALAT↓, *AST↓, *ALP↓, *LDH↓, *ROS↓, *TNF-α↓, *FFA/NEFA↓, *TG/TAG↓, *GSH↑, *GSR↑, *SOD↑, *GSH/GSSG↑, *AMPK↑, *PPARα↑, *CPT1A↑, *NF-kB↓, *SREBP1/SREBF1↓, *Fas↓, *SCD1↓, *lipid-P↓,
7954- RT,    Rutin : therapeutic potential and recent advances in drug delivery
- Review, Nor, NA - Review, IBD, NA
*antiOx↑, *antiAll↑, *Inflam↓, *AntiTum↑, *Bacteria↓, *AntiViral↑, *BioAv↓, *AntiArt↑, *PLA2↓, *chemoP↑, *ROS↓, *Casp3↓, *TNF-α↓, *NF-kB↓, *cardioP↑, *Stroke↓, *TG/TAG↓, *FFA/NEFA↓, *LDL↓, *HDL↑, *AntiDiabetic↑, *MPO↓, *NF-kB↓, *BioAv↓, *BioAv↝,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

Acetyl-CoA↓, 1,   ACLY↓, 1,   ATGL/PNPLA2↓, 1,   FFA/NEFA↓, 1,   Glycolysis↓, 1,   GSK‐3β↑, 1,   HSL/LIPE↓, 1,   p‑HSL/LIPE↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   cl‑Casp3↑, 1,   Fas↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   p‑Akt↓, 1,   p‑mTOR↓, 1,   PDE3B↓, 1,   PI3K↓, 1,   p‑PKA↓, 1,   Rictor↓, 1,   STK11/LKB1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   LC3II↑, 1,   TumAuto↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

IGF-1↓, 2,   TumCG↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,  
Total Targets: 28

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   GSH↑, 1,   GSH/GSSG↑, 1,   GSR↑, 1,   HDL↑, 1,   lipid-P↓, 1,   MPO↓, 1,   ROS↓, 3,   SOD↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   AMPK↑, 1,   CPT1A↑, 1,   FASN↓, 1,   FFA/NEFA↓, 4,   FFA/NEFA↝, 1,   glucose↝, 1,   KeyT↝, 1,   LDL↓, 2,   NH3↓, 1,   PLA2↓, 1,   SCD1↓, 1,   SREBP1/SREBF1↓, 1,  

Cell Death(tgid=5) ⓘ

Casp3↓, 1,   Fas↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

MAPK↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 2,   NF-kB↓, 4,   TNF-α↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARα↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↝, 1,   Dose↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   colonLen↑, 1,   IRes↓, 2,   KeyT↝, 1,   LDH↓, 1,   TG/TAG↓, 3,  

Functional Outcomes(tgid=23) ⓘ

antiAll↑, 1,   AntiArt↑, 1,   AntiDiabetic↑, 2,   AntiTum↑, 1,   cardioP↑, 1,   chemoP↑, 1,   fatigue↓, 1,   hepatoP↑, 1,   Stroke↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,   Bacteria↓, 1,  
Total Targets: 51

Scientific Paper Hit Count for: FFA/NEFA, Free fatty acids — FFA / non-esterified fatty acids, NEFA
1 Formononetin
1 Inositol
1 L-ornithine
1 Mangiferin
1 Patchouli Oil (Pogostemon cablin)
1 Rutin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1551  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page